BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 28, 2005
 |  BioCentury  |  Strategy

Curacyte's building blocks

Curacyte AG added one preclinical compound in its inflammatory focus area, along with chemistry expertise, with last week's stock acquisition of IBFB Pharma GmbH. The deal is the first of several steps the company plans to take to make it a more attractive candidate for either an IPO or a trade sale.

Following the deal, Curacyte (Munich, Germany) has a pipeline consisting of a compound in Phase III and Phase I trials for two indications, plus five projects in preclinical development. Curacyte aims to out-license two of the preclinical projects and to acquire an additional clinical stage compound (see "Curacyte's Pipeline").

When it was founded in 2000, Curacyte did not have a clear-cut technology or therapeutic focus, although it did have expertise in cancer and immunology that it used to scan the therapeutic universe for opportunities (see BioCentury, June 17, 2002).

In 2002, Curacyte acquired VitaResc Biotech AG, giving it a lead product, the nitric oxide scavenger PHP (pyridoxalated hemoglobin polyoxyethylene conjugate) to treat NO-induced shock (see...

Read the full 837 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >